![Emily Hill](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Emily Hill
Directeur Financier/CFO chez
REPLIMUNE GROUP, INC.
Fortune : 2 M $ au 31/05/2026
Profil
Emily Hill currently works at Replimune, Inc., as Chief Financial Officer from 2023 and Replimune Group, Inc., as Chief Financial Officer from 2023.
Ms. Hill also formerly worked at Greenhill Humane Society SPCA, as Director, Warner Chilcott Plc, as Director-Investor Relations from 2011 to 2012, Genzyme Corp., as Senior Manager-Investor Relations from 2008 to 2010, PTC Therapeutics, Inc., as SVP & Head-Investor Relations from 2018 to 2019, and Summer Street Capital Partners LLC, as Associate-Biotech Equity Research.
Ms. Hill received her undergraduate degree in 2002 from Hamilton College (New York), graduate degree in 2006 from Tufts University School of Medicine, and Masters Business Admin degree in 2011 from Fordham Gabelli School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/05/2026 | 236 556 ( 0,3 % ) | 2 M $ | 31/05/2026 |
Postes actifs de Emily Hill
| Sociétés | Poste | Début |
|---|---|---|
| REPLIMUNE GROUP, INC. | Directeur Financier/CFO | 19/09/2023 |
Replimune, Inc.
 Replimune, Inc. Pharmaceuticals: OtherHealth Technology Part of Replimune Group, Inc., Replimune, Inc. is an American clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform, which is based on a herpes simplex virus type 1 backbone engineered to selectively destroy tumor cells, modify the tumor microenvironment, and induce a systemic anti-tumor immune response with enhanced T-cell activation. The company is located in the US. The company’s therapies are designed for direct injection into tumors to trigger local destruction and systemic immune activation, potentially overcoming resistance to existing immunotherapies. Its clinical pipeline includes candidates such as RP1 and RP2, being evaluated in advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma. Key clinical trials include the phase 3 IGNYTE-3 trial of RP1 with nivolumab in advanced melanoma, the ARTACUS trial for transplant patients with skin cancers, the REVEAL study in uveal melanoma, and the RP2-003 trial in liver cancer. Replimune retains commercial rights to its therapies and collaborates with partners for supply of checkpoint inhibitors used in combination regimens. The company also supports independent clinical investigations and funds medical education initiatives in oncology. | Directeur Financier/CFO | 01/09/2023 |
Anciens postes connus de Emily Hill
| Sociétés | Poste | Fin |
|---|---|---|
Warner Chilcott Plc
 Warner Chilcott Plc Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Investor Relations Contact | 01/11/2012 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Investor Relations Contact | 01/01/2010 |
Summer Street Capital Partners LLC
 Summer Street Capital Partners LLC Investment ManagersFinance Summer Street Capital Partners invests in companies located in the United States and Canada. The firm focuses on companies operating in the fields of diverse industries with a particular interest in the niche manufacturing business & industrial services, distribution and environmental sectors. It provides financing for buyouts, MBOs, growth capital, family transitions, corporate divestitures and recapitalization transactions. | Corporate Officer/Principal | - |
| PTC THERAPEUTICS, INC. | Directeur Financier/CFO | - |
Greenhill Humane Society SPCA
 Greenhill Humane Society SPCA Miscellaneous Commercial ServicesCommercial Services Provides shelter for animals | Directeur/Membre du Conseil | - |
Formation de Emily Hill
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
75
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Hamilton College (New York)
 Hamilton College (New York) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Summer Street Capital Partners LLC
Summer Street Capital Partners LLC Investment ManagersFinance Summer Street Capital Partners invests in companies located in the United States and Canada. The firm focuses on companies operating in the fields of diverse industries with a particular interest in the niche manufacturing business & industrial services, distribution and environmental sectors. It provides financing for buyouts, MBOs, growth capital, family transitions, corporate divestitures and recapitalization transactions. | Finance |
Greenhill Humane Society SPCA
Greenhill Humane Society SPCA Miscellaneous Commercial ServicesCommercial Services Provides shelter for animals | Commercial Services |
Warner Chilcott Plc
Warner Chilcott Plc Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
Tufts University School of Medicine
 Tufts University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Replimune Group, Inc.
 Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Replimune, Inc.
Replimune, Inc. Pharmaceuticals: OtherHealth Technology Part of Replimune Group, Inc., Replimune, Inc. is an American clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform, which is based on a herpes simplex virus type 1 backbone engineered to selectively destroy tumor cells, modify the tumor microenvironment, and induce a systemic anti-tumor immune response with enhanced T-cell activation. The company is located in the US. The company’s therapies are designed for direct injection into tumors to trigger local destruction and systemic immune activation, potentially overcoming resistance to existing immunotherapies. Its clinical pipeline includes candidates such as RP1 and RP2, being evaluated in advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma. Key clinical trials include the phase 3 IGNYTE-3 trial of RP1 with nivolumab in advanced melanoma, the ARTACUS trial for transplant patients with skin cancers, the REVEAL study in uveal melanoma, and the RP2-003 trial in liver cancer. Replimune retains commercial rights to its therapies and collaborates with partners for supply of checkpoint inhibitors used in combination regimens. The company also supports independent clinical investigations and funds medical education initiatives in oncology. | Health Technology |
Fordham Gabelli School of Business
 Fordham Gabelli School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
